Natural Compounds for the Management of Parkinson's Disease and Attention-Deficit/Hyperactivity Disorder.
Juan Carlos CoronaPublished in: BioMed research international (2018)
Parkinson's disease (PD) is the second most common neurodegenerative disorder with an unknown aetiology. The pathogenic mechanisms include oxidative stress, mitochondrial dysfunction, protein dysfunction, inflammation, autophagy, apoptosis, and abnormal deposition of α-synuclein. Currently, the existing pharmacological treatments for PD cannot improve fundamentally the degenerative process of dopaminergic neurons and have numerous side effects. On the other hand, attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder of childhood and is characterised by hyperactivity, impulsivity, and inattention. The aetiology of ADHD remains unknown, although it has been suggested that its pathophysiology involves abnormalities in several brain regions, disturbances of the catecholaminergic pathway, and oxidative stress. Psychostimulants and nonpsychostimulants are the drugs prescribed for the treatment of ADHD; however, they have been associated with increased risk of substance use and have several side effects. Today, there are very few tools available to prevent or to counteract the progression of such neurological disorders. Thus, therapeutic approaches with high efficiency and fewer side effects are needed. This review presents a brief overview of the two neurological disorders and their current treatments, followed by a discussion of the natural compounds which have been studied as therapeutic agents and the mechanisms underlying the beneficial effects, in particular, the decrease in oxidative stress.
Keyphrases
- attention deficit hyperactivity disorder
- oxidative stress
- autism spectrum disorder
- high efficiency
- diabetic rats
- dna damage
- ischemia reperfusion injury
- induced apoptosis
- working memory
- cerebral ischemia
- endoplasmic reticulum stress
- cell death
- white matter
- signaling pathway
- multiple sclerosis
- brain injury
- cell cycle arrest
- binding protein
- subarachnoid hemorrhage
- early life
- congenital heart disease